S-1 Impact 6/10 Ipo / Direct Listing

$MXRX · MED-X, INC.

November 19, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Med-X, Inc. filed Amendment No. 5 to its S-1 to register resale of up to 16,248,842 post-split common shares by existing stockholders in connection with a direct listing on Nasdaq Global Market under symbol MXRX. The company raised approximately $38,081,204 in net proceeds from inception (Feb 14, 2014) through Oct 14, 2026 at an average post-split price of $2.89 per share. A 1-for-2 reverse stock split was approved June 1, 2026, effective before listing. The company will not receive proceeds from stockholder resales.

  • Registers resale of up to 16,248,842 post-split common shares via Nasdaq direct listing.
  • No firm-commitment underwriter; Maxim Group LLC engaged as financial advisor.
  • Raised ~$38,081,204 net proceeds from inception through Oct 14, 2026 at avg $2.89/share post-split.
  • 1-for-2 reverse stock split approved June 1, 2026, effective before listing.
  • Chairman/CEO controls ~54.3% of total voting power via Series A super voting preferred stock.

Price data unavailable.

A micro-cap natural-products company is pursuing a Nasdaq direct listing with no underwriter, concentrated insider voting control, and ongoing net losses.

Direct listing without a firm-commitment underwriter is a novel listing method that can produce higher opening volatility than a traditional IPO.

Nasdaq listing approval is not assured and is a condition to the offering; failure means the direct listing is terminated. No public market currently exists and private transaction prices may bear little relation to the opening public price.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →